Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
11.65
-0.04 (-0.34%)
Sep 6, 2024, 4:00 PM EDT - Market closed
Amicus Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Amicus Therapeutics stock have an average target of 16.88, with a low estimate of 13 and a high estimate of 22. The average target predicts an increase of 44.89% from the current stock price of 11.65.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for FOLD stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 3 | 3 | 3 | 3 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 8 | 8 | 8 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Initiates $18 | Strong Buy | Initiates | $18 | +54.51% | Sep 6, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $17 → $16 | Buy | Maintains | $17 → $16 | +37.34% | Aug 16, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 9, 2024 |
| Guggenheim | Guggenheim | Hold → Strong Buy Upgrades $13 | Hold → Strong Buy | Upgrades | $13 | +11.59% | May 14, 2024 |
| UBS | UBS | Strong Buy Maintains $20 → $19 | Strong Buy | Maintains | $20 → $19 | +63.09% | May 10, 2024 |
Financial Forecast
Revenue This Year
527.36M
from 399.36M
Increased by 32.05%
Revenue Next Year
652.93M
from 527.36M
Increased by 23.81%
EPS This Year
-0.19
from -0.51
EPS Next Year
0.22
from -0.19
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 549.5M | 714.2M | 1.0B | ||
| Avg | 527.4M | 652.9M | 827.9M | ||
| Low | 500.1M | 589.4M | 672.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 37.6% | 35.4% | 56.5% | ||
| Avg | 32.1% | 23.8% | 26.8% | ||
| Low | 25.2% | 11.8% | 2.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.12 | 0.44 | 1.00 | ||
| Avg | -0.19 | 0.22 | 0.64 | ||
| Low | -0.29 | 0.13 | 0.42 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 352.2% | ||
| Avg | - | - | 192.0% | ||
| Low | - | - | 91.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.